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Pulmonary arterial hypertension (PAH)
is a progressive disease characterized by
pulmonary vascular remodeling and right
heart failure. In its advanced stage, PAH
demonstrates muscularization of distal
pulmonary arterioles, concentric thicken-
ing, and obstruction of vascular lumen due
to the proliferation of pulmonary artery
endothelial cells (PAECs) and pulmonary
artery smooth muscle cells (PASMCs)
(Steiner et al., 2009). Ultimately, such arte-
riopathy in PAH leads to a life threat-
ening increase in resistance of PAECs
and PASMCs to apoptosis. However, the
molecular and cellular basis for vascular
remodeling in PAH has not been eluci-
dated. This pathogenesis of PAH shares
similarities with cancer, in which angio-
genesis is characterized by an increase in
proliferating endothelial cells and atyp-
ical morphology of tumor vasculature
(Hoff and Machado, 2012). Several stud-
ies suggest that micro-RNAs (miRNAs)
play vital roles in cancerous cells. The
miRNA 7–19 cluster located on chromo-
some 13 consists of 7 miRNAs and was
among the first miRNA clusters described
and upregulated in lung cancer (Billeter
et al., 2012). Additionally, miR-206s reg-
ulates proliferation, apoptosis and dif-
ferentiation of PASMCs (Jalali et al.,
2012). miR-16’s overexpression in alveolar
epithelial (A549) cells downregulates sero-
tonin transporter (SERT) and upregulates
epithelial sodium channel, EnaCβ, in the
presence of serotonin (Parthasarathy et al.,
2012). Given an increased understanding
of miRNAs’ roles in cancer and the sim-
ilarities between angiogenesis in cancer
and PAH, recent research relating miRNAs
to pulmonary pathogenesis present a cru-
cial need for more comprehensive studies
about miRNAs’ importance in PAH.
In the January 2013 edition of Nature
Medicine, Kim et al. augmented the under-
standing of miRNAs role with exciting
findings on miRNA-dependent associa-
tion between apelin (APLN) and fibroblast
growth factor 2 (FGF2) in PAH. Kim et al.
studied angiogenic growth factors in nor-
mal PAECs with APLN knockdown and
APLN and FGF2 mRNA levels in normal
and PAH-PAECs (Kim et al., 2013). From
these vital studies, the researchers revealed
that a disruption of APLN signaling in
PAECs results in increased expression of
FGF2 and its receptor, FGFR1. Out of the
14 different types of miRNAs analyzed,
Kim et al.’s critical experiment demon-
strated that miR-424 and miR-503 were
the most regulated microRNAs by APLN.
The study suggested that transcription of
miR-424 and miR-503, instead of their
post transcriptional phase, is regulated
by APLN signaling, since APLN knock-
down caused downregulation of both pri
and mature miR-424 and miR-503. The
researchers studied the effects of miR-424
and miR-503 overexpression or knock-
down on FGF2 and FGFR1 expression in
normal and PAH-PAECs. Consequently,
the experiment concluded that miR-424
and miR-503 regulate FGF2 and FGFR1,
which are the key factors in endothelial
FGF signaling process. The research con-
cluded that the downregulation of APLN,
miR-424 and miR-503 in PAH-PAECs
increases FGF2 and FGFR1 expression and
causes hyperproliferation of PAECs and
PASMCs. To further investigate these miR-
NAs’ role in the recovery of PAH-PAECs,
the work demonstrated that miR-424 and
miR-503 overexpression could inhibit the
proliferation of PAECs in both normal and
PAH samples by arresting the cell cycle
at G0/GI stage. Interestingly, Kim et al.’s
study results suggested that these miRNAs
could affect proliferation of PASMCs in a
paracrine manner. Most importantly, the
experiment with rat models further vali-
dated the signaling axis between miR-424,
miR-502, FGF2, and FGFR1. By intranasal
administration of GFP-expressing control
lentivirus or lentivirus expressing miR-
424, miR-503, and GFP (424/503-GFP) to
the rat models, the researchers found a
reduction in right ventricular systolic pres-
sure, fewer proliferating cellular nuclear
antigens (PCNA), and a decreased expres-
sion of FGF2 and FGFR1 in 424/503-
GFP treatment models. Therefore, the
study concluded that the restoration of
miR-424 and miR-503 inhibits FGF2 and
FGFR1 expression and alleviates PAH
pathogenesis.
With the use of experimental models
of rodents and human alveolar-endothelial
and smooth muscle cells at different stages
of their study, Kim et al. have pro-
vided an extraordinary sense of opti-
mism in the scientific community’s search
for more insights in pulmonary patho-
genesis. However, Kim et al.’s study of
the APLN-FGF link mediated by miR-
NAs compared only 14 miRNAs, which
limited the study to only those miRNAs,
even though a large number of miRNAs
have been identified thus far. Further, the
study results based on mmu-miR-322 and
rno-miR-322, which are the mouse and
rat homologs of has-miR-424, respectively,
might provide an initial assessment; how-
ever, the application of the study results
in humans with PAH truly depends on
how comparative those homologs are to
their corresponding miRNA within the
human body. These study results can be
further strengthened by clinical experi-
ments in humans with PAH. Additionally,
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the plurality of miRNAs’ targets, in addi-
tion to FGFR2, can warrant a more com-
prehensive knowledge of the molecular
and cellular pathways. Despite the lim-
itations, Kim et al. provided eloquent
data that permits a rejuvenating guide
for scientific studies to examine whether
miRNAs can be used as biomarkers ver-
sus regulators of pulmonary pathophys-
iology. Hopefully, Kim et al.’s findings
and other miRNA related studies will
provide a foundation for exploration of
therapeutic models for finding a cure
for PAH.
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